<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569803</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-046</org_study_id>
    <nct_id>NCT00569803</nct_id>
  </id_info>
  <brief_title>Subcutaneous Pharmacokinetics of Belatacept</brief_title>
  <official_title>Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept
      Administered Subcutaneously to Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Serum Concentration (Tmax) of Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Half-life (T-HALF) of Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CLT/F) of SC Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CLT) of IV Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady State (VSS) for IV Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption</measure>
    <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
    <description>AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug*h/mL).
AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration.
AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities</measure>
    <time_frame>1 day pre-dose, Days 1, 2, 5, 14, 28, 42, 86 and 116</time_frame>
    <description>Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Injection Site Reactions</measure>
    <time_frame>0.5, 2, 6 and 24 hours post-dose, Days 3, 4, 5, 6, 7, 8, 14, 21 and 116</time_frame>
    <description>Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Physical Examination Abnormalities</measure>
    <time_frame>Days 1, 2, 5, 14, 28, 42, 86, 116</time_frame>
    <description>All clinically significant deviations from normal physical examinations were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Days 1 and 116</time_frame>
    <description>Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Hematology Laboratory Abnormalities</measure>
    <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (*10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx).
Leukocytes (*10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre-Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN) Neutrophils+Bands (*10^3 c/uL): &lt;=1.500. Lymphocytes (*10^3 c/uL): &lt;0.750 or &gt;7.500. Monocytes (*10^3 c/uL): &gt;2.000. Basophils (*10^3 c/uL): &gt;0.400. Eosinophils (*10^3 c/uL): &gt;0.750.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Serum Chemistry Abnormalities</measure>
    <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (mg/dL): &gt;1.33*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): &lt;0.95*LLN, &gt;1.05*ULN (if Pre-Rx&lt;LLN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN).
Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Laboratory Abnormalities</measure>
    <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Glucose (mg/dL): &lt;0.8*LLN, &gt;1.5*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN).
Protein (grams per deciliter: g/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Albumin (g/dL): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mg.dL): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Immunogenicity to Belatacept</measure>
    <time_frame>Days 1, 14, 28, 42, 56, 86, 116</time_frame>
    <description>The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Transplantation</condition>
  <arm_group>
    <arm_group_label>Belatacept 50 mg Subcutaneous Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belatacept 50 mg subcutaneous (SC) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 100 mg Subcutaneous Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belatacept 100 mg SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 125 mg Subcutaneous Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Belatacept 125 mg SC injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 150 mg Subcutaneous Injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 SC injections of 75 mg Belatacept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 200 mg Subcutaneous Injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 SC injections of 100 mg Belatacept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 250 mg Subcutaneous Injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 SC injections of 125 mg Belatacept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 125 mg Intravenous Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125 mg Belatacept intravenous (IV) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC injection of placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belatacept</intervention_name>
    <description>single dose, 116 days</description>
    <arm_group_label>Belatacept 50 mg Subcutaneous Injection</arm_group_label>
    <arm_group_label>Belatacept 100 mg Subcutaneous Injection</arm_group_label>
    <arm_group_label>Belatacept 125 mg Subcutaneous Injection</arm_group_label>
    <arm_group_label>Belatacept 150 mg Subcutaneous Injections</arm_group_label>
    <arm_group_label>Belatacept 200 mg Subcutaneous Injections</arm_group_label>
    <arm_group_label>Belatacept 250 mg Subcutaneous Injections</arm_group_label>
    <arm_group_label>Belatacept 125 mg Intravenous Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18 to 65 years old

          -  Subjects must weigh less than or equal to 100 kg

        Exclusion Criteria:

          -  Inability to tolerate injections or IV infusions

          -  autoimmune disorders

          -  TB

          -  herpes

          -  HCV

          -  HBV

          -  HIV

          -  bacterial or viral infection

          -  history of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ppd Development</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <results_first_submitted>July 5, 2016</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>153 participants were enrolled, with 106 discontinuing prior to study drug administration because they no longer met study criteria or they withdrew consent. 47 participants met all eligibility criteria and received study medication. 1 subject, who received an incomplete dose due to an injection syringe leak, was replaced.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Belatacept 50 mg Subcutaneous Injection</title>
          <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
        </group>
        <group group_id="P2">
          <title>Belatacept 100 mg Subcutaneous Injection</title>
          <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
        </group>
        <group group_id="P3">
          <title>Belatacept 125 mg Subcutaneous Injection</title>
          <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
        </group>
        <group group_id="P4">
          <title>Belatacept 150 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="P5">
          <title>Belatacept 200 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="P6">
          <title>Belatacept 250 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="P7">
          <title>Belatacept 125 mg Intravenous Infusion</title>
          <description>125 mg Belatacept intravenous (IV) injection</description>
        </group>
        <group group_id="P8">
          <title>Placebo</title>
          <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="10"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>injection syringe leaked during dosing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belatacept 50 mg Subcutaneous Injection</title>
          <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
        </group>
        <group group_id="B2">
          <title>Belatacept 100 mg Subcutaneous Injection</title>
          <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
        </group>
        <group group_id="B3">
          <title>Belatacept 125 mg Subcutaneous Injection</title>
          <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
        </group>
        <group group_id="B4">
          <title>Belatacept 150 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="B5">
          <title>Belatacept 200 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="B6">
          <title>Belatacept 250 mg Subcutaneous Injections</title>
          <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="B7">
          <title>Belatacept 125 mg Intravenous Infusion</title>
          <description>125 mg Belatacept intravenous (IV) injection</description>
        </group>
        <group group_id="B8">
          <title>Placebo</title>
          <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="11"/>
                    <measurement group_id="B2" value="27" spread="12"/>
                    <measurement group_id="B3" value="28" spread="12"/>
                    <measurement group_id="B4" value="34" spread="18"/>
                    <measurement group_id="B5" value="31" spread="11"/>
                    <measurement group_id="B6" value="31" spread="10"/>
                    <measurement group_id="B7" value="32" spread="16"/>
                    <measurement group_id="B8" value="27" spread="6"/>
                    <measurement group_id="B9" value="30" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Serum Concentration (Cmax) of Belatacept</title>
        <description>Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) of Belatacept</title>
          <description>Maximum observed serum concentration (Cmax) values were derived from serum concentration versus time data and reported in micrograms per milliliter (ug/mL).</description>
          <population>All participants treated with Belatacept</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="30"/>
                    <measurement group_id="O2" value="6.2" spread="34"/>
                    <measurement group_id="O3" value="8.5" spread="50"/>
                    <measurement group_id="O4" value="11.1" spread="19"/>
                    <measurement group_id="O5" value="14.5" spread="16"/>
                    <measurement group_id="O6" value="14.5" spread="18"/>
                    <measurement group_id="O7" value="42.4" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Serum Concentration (Tmax) of Belatacept</title>
        <description>Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Serum Concentration (Tmax) of Belatacept</title>
          <description>Time of maximum observed serum concentration (Tmax) values were derived from serum concentration versus time data for all participants treated with Belatacept.</description>
          <population>All participants treated with Belatacept</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="36" upper_limit="96"/>
                    <measurement group_id="O2" value="60" lower_limit="48" upper_limit="120"/>
                    <measurement group_id="O3" value="96" lower_limit="48" upper_limit="144"/>
                    <measurement group_id="O4" value="60" lower_limit="36" upper_limit="96"/>
                    <measurement group_id="O5" value="60" lower_limit="24" upper_limit="84"/>
                    <measurement group_id="O6" value="72" lower_limit="60" upper_limit="96"/>
                    <measurement group_id="O7" value="0.5" lower_limit="0.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept</title>
        <description>Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL).</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-T)) for Belatacept</title>
          <description>Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL).</description>
          <population>All participants treated with Belatacept</population>
          <units>ug*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2587" lower_limit="2132" upper_limit="3139"/>
                    <measurement group_id="O2" value="1848" lower_limit="1523" upper_limit="2242"/>
                    <measurement group_id="O3" value="2371" lower_limit="1954" upper_limit="2876"/>
                    <measurement group_id="O4" value="2703" lower_limit="2228" upper_limit="3280"/>
                    <measurement group_id="O5" value="2650" lower_limit="2184" upper_limit="3215"/>
                    <measurement group_id="O6" value="2193" lower_limit="1807" upper_limit="2660"/>
                    <measurement group_id="O7" value="3023" lower_limit="2637" upper_limit="3466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 50mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 100mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 125mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 150mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 200mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 250mg SC over 125mg IV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept</title>
        <description>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL)</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Geometric Means of Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) for Belatacept</title>
          <description>Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was derived from serum concentration versus time data. Adjusted geometric means were reported in microgram hours per milliliter (ug*h/mL)</description>
          <population>All participants treated with Belatacept</population>
          <units>ug*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2639" lower_limit="2172" upper_limit="3205"/>
                    <measurement group_id="O2" value="1851" lower_limit="1524" upper_limit="2248"/>
                    <measurement group_id="O3" value="2380" lower_limit="1959" upper_limit="2891"/>
                    <measurement group_id="O4" value="2719" lower_limit="2238" upper_limit="3303"/>
                    <measurement group_id="O5" value="2666" lower_limit="2194" upper_limit="3238"/>
                    <measurement group_id="O6" value="2201" lower_limit="1812" upper_limit="2673"/>
                    <measurement group_id="O7" value="3031" lower_limit="2642" upper_limit="3478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 50mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 100mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 125mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 150mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 200mg SC over 125mg IV</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Ratio of Geometric Means: 250mg SC over 125mg IV</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Half-life (T-HALF) of Belatacept</title>
        <description>Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Half-life (T-HALF) of Belatacept</title>
          <description>Serum half-life (T-HALF) was determined from serum concentration versus time data and was reported in hours.</description>
          <population>All participants treated with Belatacept</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="25.7"/>
                    <measurement group_id="O2" value="100" spread="10.1"/>
                    <measurement group_id="O3" value="135" spread="47.6"/>
                    <measurement group_id="O4" value="158" spread="46.9"/>
                    <measurement group_id="O5" value="161" spread="45.3"/>
                    <measurement group_id="O6" value="150" spread="43.6"/>
                    <measurement group_id="O7" value="130" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CLT/F) of SC Belatacept</title>
        <description>Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with SC Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CLT/F) of SC Belatacept</title>
          <description>Apparent total body clearance (CLT/F) was derived from serum concentration versus time data for all participants who received subcutaneous (SC) Belatacept injections. Units reported in milliliters per hour (mL/h).</description>
          <population>All participants treated with SC Belatacept</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="27"/>
                    <measurement group_id="O2" value="67.5" spread="34"/>
                    <measurement group_id="O3" value="52.5" spread="31"/>
                    <measurement group_id="O4" value="46.0" spread="26"/>
                    <measurement group_id="O5" value="46.9" spread="21"/>
                    <measurement group_id="O6" value="56.8" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CLT) of IV Belatacept</title>
        <description>Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with IV Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CLT) of IV Belatacept</title>
          <description>Total body clearance (CLT) was derived from serum concentration versus time data for all participants that were treated with IV Belatacept. Units reported in milliliters per hour (mL/h)</description>
          <population>All participants treated with IV Belatacept</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution at Steady State (VSS) for IV Belatacept</title>
        <description>Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with IV Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (VSS) for IV Belatacept</title>
          <description>Volume of distribution at steady state (VSS) was derived from serum concentration versus time data for all participants treated with IV Belatacept.</description>
          <population>All participants treated with IV Belatacept</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept</title>
        <description>Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with SC Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Steady State (Vss/F) for SC Belatacept</title>
          <description>Apparent volume of distribution at steady state (Vss/F) was derived from concentration versus time data for all participants treated with subcutaneous (SC) Belatacept.</description>
          <population>All participants treated with SC Belatacept</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.79" spread="31.02"/>
                    <measurement group_id="O2" value="15.30" spread="28.79"/>
                    <measurement group_id="O3" value="14.12" spread="36.63"/>
                    <measurement group_id="O4" value="12.75" spread="14.20"/>
                    <measurement group_id="O5" value="13.34" spread="13.77"/>
                    <measurement group_id="O6" value="15.82" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption</title>
        <description>AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug*h/mL).
AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration.
AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.</description>
        <time_frame>Immediately before dose, 0.5, 2, 6, 12, 24, 36, 48, 60, 72, 84 hours post-dose, Days 5, 6, 7, 8, 14, 21, 28, 35, 42, 56, 86 and 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>1 Injection Site</title>
            <description>Participants receiving treatments of 50mg, 100mg and 125mg Subcutaneous Belatacept were injected at 1 site at the anterior thigh.</description>
          </group>
          <group group_id="O2">
            <title>2 Injection Sites</title>
            <description>Participants receiving treatments of 150mg, 200mg and 250mg Subcutaneous Belatacept were injected at 2 sites; one injection equal to half the total dose was delivered to the anterior thigh on each side.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Number of Injection Sites on Subcutaneous Belatacept Absorption</title>
          <description>AUC(0-T) and AUC(INF) for Belatacept were derived from serum concentration versus time data to assess the effect of number of injection sites on the subcutaneous absorption of Belatacept. All treatments were dose-normalized to 50mg. Adjusted geometric means reported in microgram hours per milliliter (ug*h/mL).
AUC(0-T) = Area Under the Serum Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration.
AUC(INF) = Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time.</description>
          <population>All participants treated with Belatacept</population>
          <units>ug*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-T)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="898" lower_limit="794" upper_limit="1017"/>
                    <measurement group_id="O2" value="1002" lower_limit="885" upper_limit="1134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(INF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="906" lower_limit="799" upper_limit="1027"/>
                    <measurement group_id="O2" value="1007" lower_limit="888" upper_limit="1142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>AUC(0-T) Ratio of Geometric Means: 1 injection site over 2 injection sites</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>AUC(INF) Ratio of Geometric Means: 1 injection site over 2 injection sites</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Sign Abnormalities</title>
        <description>Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.</description>
        <time_frame>1 day pre-dose, Days 1, 2, 5, 14, 28, 42, 86 and 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities</title>
          <description>Vital signs (body temperature, respiratory rate, seated blood pressure, and heart rate) were recorded at screening. All significant findings were evaluated by the investigator, and all abnormalities were listed.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Injection Site Reactions</title>
        <description>Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.</description>
        <time_frame>0.5, 2, 6 and 24 hours post-dose, Days 3, 4, 5, 6, 7, 8, 14, 21 and 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection Site Reactions</title>
          <description>Participants were assessed for erythema, heat, pain, pruritis and swelling at the injection sites and were characterized by the investigator as mild, moderate or severe reactions.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mild reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Physical Examination Abnormalities</title>
        <description>All clinically significant deviations from normal physical examinations were reported.</description>
        <time_frame>Days 1, 2, 5, 14, 28, 42, 86, 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physical Examination Abnormalities</title>
          <description>All clinically significant deviations from normal physical examinations were reported.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Abnormalities</title>
        <description>Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.</description>
        <time_frame>Days 1 and 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Abnormalities</title>
          <description>Participants underwent a 12-lead ECG assessment at Screening (Day 1) and Study Discharge (Day 116). All investigator-assessed ECG abnormalities were reported.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Discharge (Day 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Hematology Laboratory Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (*10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx).
Leukocytes (*10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre-Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN) Neutrophils+Bands (*10^3 c/uL): &lt;=1.500. Lymphocytes (*10^3 c/uL): &lt;0.750 or &gt;7.500. Monocytes (*10^3 c/uL): &gt;2.000. Basophils (*10^3 c/uL): &gt;0.400. Eosinophils (*10^3 c/uL): &gt;0.750.</description>
        <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Hematology Laboratory Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (*10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx).
Leukocytes (*10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre-Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN) Neutrophils+Bands (*10^3 c/uL): &lt;=1.500. Lymphocytes (*10^3 c/uL): &lt;0.750 or &gt;7.500. Monocytes (*10^3 c/uL): &gt;2.000. Basophils (*10^3 c/uL): &gt;0.400. Eosinophils (*10^3 c/uL): &gt;0.750.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + Bands (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (absolute)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Serum Chemistry Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (mg/dL): &gt;1.33*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): &lt;0.95*LLN, &gt;1.05*ULN (if Pre-Rx&lt;LLN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN).
Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
        <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Serum Chemistry Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx).
Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (mg/dL): &gt;1.33*Pre-Rx. Sodium (milliequivalents per Liter: mEq/L): &lt;0.95*LLN, &gt;1.05*ULN (if Pre-Rx&lt;LLN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN).
Potassium(mEq/L), Chloride (mEq/L), Calcium(mg/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Urea Nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, Inorganic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Laboratory Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Glucose (mg/dL): &lt;0.8*LLN, &gt;1.5*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN).
Protein (grams per deciliter: g/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Albumin (g/dL): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mg.dL): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
        <time_frame>Day 1 Pre-dose, Days 2, 5, 14, 28, 42, 86, 116</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
          <group group_id="O8">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Laboratory Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities:
Glucose (mg/dL): &lt;0.8*LLN, &gt;1.5*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN).
Protein (grams per deciliter: g/dL): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN).
Albumin (g/dL): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mg.dL): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, Fasting Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Immunogenicity to Belatacept</title>
        <description>The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.</description>
        <time_frame>Days 1, 14, 28, 42, 56, 86, 116</time_frame>
        <population>All participants treated with Belatacept</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 50 mg Subcutaneous Injection</title>
            <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 100 mg Subcutaneous Injection</title>
            <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
          </group>
          <group group_id="O3">
            <title>Belatacept 125 mg Subcutaneous Injection</title>
            <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
          </group>
          <group group_id="O4">
            <title>Belatacept 150 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O5">
            <title>Belatacept 200 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O6">
            <title>Belatacept 250 mg Subcutaneous Injections</title>
            <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
          </group>
          <group group_id="O7">
            <title>Belatacept 125 mg Intravenous Infusion</title>
            <description>125 mg Belatacept intravenous (IV) injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Immunogenicity to Belatacept</title>
          <description>The number of participants with positive immunogenicity to Belatacept was reported for each arm. Positive immunogenicity was defined as the presence of a positive antibody response generated against Belatacept.</description>
          <population>All participants treated with Belatacept</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Day 1 until 30 days post discontinuation of dosing, up to August 2008 (approximately 8 months)</time_frame>
      <desc>Study initiated: December 2007
Study completed: August 2008
Participants underwent regularly scheduled investigator assessments and clinical laboratory evaluations as described in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Belatacept 50mg SC</title>
          <description>Belatacept 50 mg subcutaneous (SC) injection into anterior thigh, 0.4 mL injection volume</description>
        </group>
        <group group_id="E2">
          <title>Belatacept 100mg SC</title>
          <description>Belatacept 100 mg SC injection into anterior thigh, 0.8 mL injection volume</description>
        </group>
        <group group_id="E3">
          <title>Belatacept 125mg SC</title>
          <description>Belatacept 125 mg SC injection into anterior thigh, 1.0 mL injection volume</description>
        </group>
        <group group_id="E4">
          <title>Belatacept 150mg SC</title>
          <description>Participants received 2 SC injections of 75 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="E5">
          <title>Belatacept 200mg SC</title>
          <description>Participants received 2 SC injections of 100 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="E6">
          <title>Belatacept 250mg SC</title>
          <description>Participants received 2 SC injections of 125 mg Belatacept each, in the anterior thighs. One injection was given in each thigh, with the second injection immediately following the first injection.</description>
        </group>
        <group group_id="E7">
          <title>Belatacept 125mg IV</title>
          <description>125 mg Belatacept intravenous (IV) injection</description>
        </group>
        <group group_id="E8">
          <title>PLACEBO</title>
          <description>Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)</description>
        </group>
        <group group_id="E9">
          <title>All Belatacept</title>
          <description>All participants treated with IV or SC Belatacept of any dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

